The high expression of CSF1R on multiple cell types (Fig. 2c) and the associated increase in Ki67+ tumor cells (Fig. 2d,e) suggested to us that targeting the CSF1/CSF1R axis might enhance palbociclib efficacy by countering CSF1R-mediated processes (Supplementary Table 4). The gene discussed is CSF1R; the disease is neoplasm.